CoChat

Assessing fitness costs in malaria parasites: a comprehensive review and implications for drug resistance management

Segovia, Xyonane, Srivastava, Bhavya, Serrato-Arroyo, Sergio, Guerrero, Ashley, Huijben, Silvie · 2025 · Malaria Journal
Cited by 12

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12936-025-05286-w

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 212

  1. Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Aye MM, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in Southern Myanmar. PLoS ONE. 2013;8: e57689. · DOI · Paper page
  2. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619–20. · DOI · Paper page
  3. Kobasa T, Talundzic E, Sug-aram R, Boondat P, Goldman IF, Lucchi NW, et al. Emergence and spread of kelch13 mutations associated with artemisinin resistance in Plasmodium falciparum parasites in 12 Thai Provinces from 2007 to 2016. Antimicrob Agents Chemother. 2018;62:e02141-e2217. · DOI
  4. Conrad MD, Asua V, Garg S, Giesbrecht D, Niaré K, Smith S, et al. Evolution of partial resistance to artemisinins in malaria parasites in Uganda. N Engl J Med. 2023;389:722–32. · DOI · Paper page
  5. Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385:1163–71. · DOI · Paper page
  6. Uwimana A, Legrand E, Stokes BH, Ndikumana JLM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;27:1113–5. · DOI · Paper page
  7. Awor P, Coppée R, Khim N, Rondepierre L, Roesch C, Khean C, et al. Indigenous emergence and spread of kelch13 C469Y artemisinin-resistant Plasmodium falciparum in Uganda. Antimicrob Agents Chemother. 2024;68: e0165923. · doi:10.1128/aac.01659-23
  8. Straimer J, Gandhi P, Renner KC, Schmitt EK. High prevalence of Plasmodium falciparum K13 mutations in Rwanda is associated with slow parasite clearance after treatment with artemether-lumefantrine. J Infect Dis. 2022;225:1411–4. · DOI
  9. Ding XC, Ubben D, Wells TN. A framework for assessing the risk of resistance for anti-malarials in development. Malar J. 2012;11:292. · DOI
  10. Huijben S, Chan BHK, Nelson WA, Read AF. The impact of within-host ecology on the fitness of a drug-resistant parasite. Evol Med Public Health. 2018;2018:127–37. · DOI
  11. Dhingra SK, Gabryszewski SJ, Small-Saunders JL, Yeo T, Henrich PP, Mok S, et al. Global spread of mutant pfcrt and its pleiotropic impact on Plasmodium falciparum multidrug resistance and fitness. MBio. 2019;30:10.
  12. Mathieu LC, Cox H, Early AM, Mok S, Lazrek Y, Paquet JC, et al. Local emergence in Amazonia of Plasmodium falciparum k13 C580Y mutants associated with in vitro artemisinin resistance. Elife. 2020;9:e51015. · DOI · Paper page
  13. Tirrell AR, Vendrely KM, Checkley LA, Davis SZ, McDew-White M, Cheeseman IH, et al. Pairwise growth competitions identify relative fitness relationships among artemisinin resistant Plasmodium falciparum field isolates. Malar J. 2019;18:295. · DOI
  14. Babiker HA, Satti G, Ferguson H, Bayoumi R, Walliker D. Drug resistant Plasmodium falciparum in an area of seasonal transmission. Acta Trop. 2005;94:260–8. · doi:10.1016/j.actatropica.2005.04.007
  15. Huijben S, Bell AS, Sim DG, Tomasello D, Mideo N, Day T, et al. Aggressive chemotherapy and the selection of drug resistant pathogens. PLoS Pathog. 2013;9: e1003578. · DOI
  16. Huijben S, Paaijmans KP. Putting evolution in elimination: winning our ongoing battle with evolving malaria mosquitoes and parasites. Evol Appl. 2017;11:415–30. · DOI · Paper page
  17. Zhang J, Cunningham JJ, Brown JS, Gatenby RA. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat Commun. 2017;8:1816. · DOI · Paper page
  18. Beardmore RE, Peña-Miller R, Gori F, Iredell J. Antibiotic cycling and antibiotic mixing: which one best mitigates antibiotic resistance? Mol Biol Evol. 2017;34:802–17.
  19. Brown EM, Nathwani D. Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. J Antimicrob Chemother. 2005;55:6–9. · DOI · Paper page
  20. Andersson DI, Levin BR. The biological cost of antibiotic resistance. Curr Opin Microbiol. 1999;2:489–93. · DOI · Paper page
  21. Lemos D, Stuart JB, Louie W, Singapuri A, Ramírez AL, Watanabe J, et al. Two sides of a coin: a Zika virus mutation selected in pregnant rhesus macaques promotes fetal infection in mice but at a cost of reduced fitness in nonpregnant macaques and diminished transmissibility by vectors. J Virol. 2020;94:e01605-e1620. · DOI
  22. Chesnokov A, Patel MC, Mishin VP, De La Cruz JA, Lollis L, Nguyen HT, et al. Replicative fitness of seasonal influenza A viruses with decreased susceptibility to baloxavir. J Infect Dis. 2020;22:367–71.
  23. Cong M, Heneine W, García-Lerma JG. The fitness cost of mutations associated with Human Immunodeficiency Virus type 1 drug resistance is modulated by mutational interactions. J Virol. 2007;81:3037–41. · DOI
  24. Ma C, Li C, Ganesan L, Oak J, Tsai S, Sept D, et al. Mutations in α-tubulin confer dinitroaniline resistance at a cost to microtubule function. Mol Biol Cell. 2007;18:4711–20. · DOI
  25. Vila-Aiub MM. Fitness of herbicide-resistant weeds: current knowledge and implications for management. Plants. 2019;8:469. · DOI
  26. Freeman JC, Smith LB, Silva JJ, Fan Y, Sun H, Scott JG. Fitness studies of insecticide resistant strains: lessons learned and future directions. Pest Manag Sci. 2021;77:3847–56. · DOI
  27. Tchouakui M, Riveron Miranda J, Mugenzi LMJ, Djonabaye D, Wondji MJ, Tchoupo M, et al. Cytochrome P450 metabolic resistance (CYP6P9a) to pyrethroids imposes a fitness cost in the major African malaria vector Anopheles funestus. Heredity. 2020;124:621–32. · DOI
  28. Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res. 2009;69:4894–903. · DOI · Paper page
  29. Kühnert D, Kouyos R, Shirreff G, Pečerska J, Scherrer AU, Böni J, et al. Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics. PLoS Pathog. 2018;14: e1006895. · DOI
  30. Taquet A, Delatte H, Barrès B, Simiand C, Grondin M, Jourdan-Pineau H. Insecticide resistance and fitness cost in Bemisia tabaci (Hemiptera: Aleyrodidae) invasive and resident species in La Réunion Island. Pest Manag Sci. 2020;76:1235–44. · DOI
  31. Vanaerschot M, Decuypere S, Berg M, Roy S, Dujardin JC. Drug-resistant microorganisms with a higher fitness—can medicines boost pathogens? Crit Rev Microbiol. 2013;39:384–94. · DOI
  32. Walliker D, Hunt P, Babiker H. Fitness of drug-resistant malaria parasites. Acta Trop. 2005;94:251–9. · doi:10.1016/j.actatropica.2005.04.005
  33. Rosenthal PJ. The interplay between drug resistance and fitness in malaria parasites. Mol Microbiol. 2013;89:1025–38. · DOI
  34. Hughes D, Andersson DI. Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat Rev Genet. 2015;16:459–71. · DOI · Paper page
  35. Boutwell CL, Rowley CF, Essex M. Reduced viral replication capacity of Human Immunodeficiency Virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. J Virol. 2009;83:2460–8. · DOI
  36. Ender M, McCallum N, Adhikari R, Berger-Bächi B. Fitness cost of SCCmec and methicillin resistance levels in Staphylococcus aureus. Antimicrob Agents Chemother. 2004;48:2295–7. · DOI
  37. Han J, Wang Y, Sahin O, Shen Z, Guo B, Shen J, et al. A fluoroquinolone resistance associated mutation in gyrA affects DNA supercoiling in Campylobacter jejuni. Front Cell Infect Microbiol. 2012;2:21. · doi:10.3389/fcimb.2012.00021
  38. Valsecchi I, Mellado E, Beau R, Raj S, Latgé JP. Fitness studies of azole-resistant strains of Aspergillus fumigatus. Antimicrob Agents Chemother. 2015;59:7866–9. · DOI · Paper page
  39. Zschaler J, Schlorke D, Arnhold J. Differences in innate immune response between man and mouse. Crit Rev Immunol. 2014;34:433–54.
  40. Maier AG, Rug M. In vitro culturing Plasmodium falciparum erythrocytic stages. In: Ménard R, editor. Malaria: methods and protocols. Totowa: Humana Press; 2013. p. 3–15.
  41. Sinnis P, Zavala F. The skin: where malaria infection and the host immune response begin. Semin Immunopathol. 2012;34:787–92. · DOI
  42. Harrison SP, Baumgarten SF, Verma R, Lunov O, Dejneka A, Sullivan GJ. Liver organoids: recent developments, limitations and potential. Front Med. 2021;8: 574047. · DOI · Paper page
  43. Nair S, Li X, Arya GA, McDew-White M, Ferrari M, Nosten F, et al. Fitness costs and the rapid spread of kelch13-C580Y substitutions conferring artemisinin resistance. Antimicrob Agents Chemother. 2018;62:e00605-e618. · DOI
  44. Balikagala B, Sakurai-Yatsushiro M, Tachibana SI, Ikeda M, Yamauchi M, Katuro OT, et al. Recovery and stable persistence of chloroquine sensitivity in Plasmodium falciparum parasites after its discontinued use in Northern Uganda. Malar J. 2020;19:76. · doi:10.1186/s12936-020-03157-0
  45. Laufer MK, Plowe CV. Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies. Drug Resist Update. 2004;7:279–88. · DOI
  46. Ecker A, Lehane AM, Clain J, Fidock DA. Pfcrt and its role in antimalarial drug resistance. Trends Parasitol. 2012;28:504–14. · doi:10.1016/j.pt.2012.08.002
  47. Duvalsaint M, Conrad MD, Tukwasibwe S, Tumwebaze PK, Legac J, Cooper RA, et al. Balanced impacts of fitness and drug pressure on the evolution of pfmdr1 polymorphisms in Plasmodium falciparum. Malar J. 2021;20:292. · DOI
  48. Shafik SH, Cobbold SA, Barkat K, Richards SN, Lancaster NS, Llinás M, et al. The natural function of the malaria parasite’s chloroquine resistance transporter. Nat Commun. 2020;11:3922. · DOI
  49. Bushman M, Morton L, Duah N, Quashie N, Abuaku B, Koram KA, et al. Within-host competition and drug resistance in the human malaria parasite Plasmodium falciparum. Proc R Soc B Biol Sci. 2016;283:20153038. · DOI
  50. Osman ME, Mockenhaupt FP, Bienzle U, Elbashir MI, Giha HA. Field-based evidence for linkage of mutations associated with chloroquine (pfcrt/pfmdr1) and sulfadoxine-pyrimethamine (pfdhfr/pfdhps) resistance and for the fitness cost of multiple mutations in P. falciparum. Infect Genet Evol. 2007;7:52–9. · doi:10.1016/j.meegid.2006.03.008
  51. Hallett RL, Sutherland CJ, Alexander N, Ord R, Jawara M, Drakeley CJ, et al. Combination therapy counteracts the enhanced transmission of drug-resistant malaria parasites to mosquitoes. Antimicrob Agents Chemother. 2004;48:3940–3. · doi:10.1128/aac.48.10.3940-3943.2004
  52. Mockenhaupt FP, Bousema JT, Eggelte TA, Ehrhardt S, Otchwemah RN, Sauerwein RW, et al. Concurrence of Plasmodium falciparum dhfr and crt mutations in northern Ghana. Malar J. 2005;4:42. · doi:10.1186/1475-2875-4-42
  53. Liu DQ, Liu RJ, Ren DX, Gao DQ, Zhang CY, Qui CP, et al. Changes in the resistance of Plasmodium falciparum to chloroquine in Hainan, China. Bull World Health Organ. 1995;73:483–6.
  54. Wang X, Mu J, Li G, Chen P, Guo X, Fu L, et al. Decreased prevalence of the Plasmodium falciparum chloroquine resistance transporter 76T marker associated with cessation of chloroquine use against P. falciparum malaria in Hainan, People’s Republic of China. Am J Trop Med Hyg. 2005;72:410–4. · doi:10.4269/ajtmh.2005.72.410
  55. Kublin JG, Cortese JF, Njunju EM, Mukadam RAG, Wirima JJ, Kazembe PN, et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis. 2003;187:1870–5. · DOI · Paper page
  56. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med. 2006;355:1959–66. · DOI · Paper page
  57. Mwanza S, Joshi S, Nambozi M, Chileshe J, Malunga P, Kabuya JBB, et al. The return of chloroquine-susceptible Plasmodium falciparum malaria in Zambia. Malar J. 2016;15:584. · DOI
  58. Bwire GM, Ngasala B, Mikomangwa WP, Kilonzi M, Kamuhabwa AAR. Detection of mutations associated with artemisinin resistance at k13-propeller gene and a near complete return of chloroquine susceptible falciparum malaria in southeast of Tanzania. Sci Rep. 2020;10:3500. · doi:10.1038/s41598-020-60549-7
  59. Gupta H, Macete E, Bulo H, Salvador C, Warsame M, Carvalho E, et al. Drug-resistant polymorphisms and copy numbers in Plasmodium falciparum, Mozambique, 2015. Emerg Infect Dis. 2018;24:40–8. · DOI
  60. Gharbi M, Flegg JA, Hubert V, Kendjo E, Metcalf JE, Bertaux L, et al. Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000–2011. Malar J. 2013;12:35. · DOI
  61. Lu F, Zhang M, Culleton RL, Xu S, Tang J, Zhou H, et al. Return of chloroquine sensitivity to Africa? Surveillance of African Plasmodium falciparum chloroquine resistance through malaria imported to China. Parasit Vectors. 2017;10:355. · DOI
  62. Njiro BJ, Mutagonda RF, Chamani AT, Mwakyandile T, Sabas D, Bwire GM. Molecular surveillance of chloroquine-resistant Plasmodium falciparum in sub-Saharan African countries after withdrawal of chloroquine for treatment of uncomplicated malaria: a systematic review. J Infect Public Health. 2022;15:550–7. · DOI
  63. Ocan M, Akena D, Nsobya S, Kamya MR, Senono R, Kinengyere AA, et al. Persistence of chloroquine resistance alleles in malaria endemic countries: a systematic review of burden and risk factors. Malar J. 2019;18:76. · DOI
  64. Moyeh MN, Fankem SN, Ali IM, Sofeu D, Sandie SM, Njimoh DL, et al. Current status of 4-aminoquinoline resistance markers 18 years after cessation of chloroquine use for the treatment of uncomplicated falciparum malaria in the littoral coastline region of Cameroon. Pathog Glob Health. 2022;116:509–14. · DOI
  65. Asare KK, Africa J, Mbata J, Opoku YK. The emergence of chloroquine-sensitive Plasmodium falciparum is influenced by selected communities in some parts of the Central Region of Ghana. Malar J. 2021;20:447. · doi:10.1186/s12936-021-03985-8
  66. Ord R, Alexander N, Dunyo S, Hallett R, Jawara M, Targett G, et al. Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian Plasmodium falciparum imply reduced fitness of chloroquine-resistant parasites. J Infect Dis. 2007;196:1613–9. · DOI · Paper page
  67. Inoue J, Lopes D, do Rosário V, Machado M, Hristov AD, Lima GF, et al. Analysis of polymorphisms in Plasmodium falciparum genes related to drug resistance: a survey over four decades under different treatment policies in Brazil. Malar J. 2014;13:372. · DOI
  68. Montenegro LM, Salas de las B, Neal AT, Tobon-Castaño A, Fairhurst RM, Lopera-Mesa TM. State of artemisinin and partner drug susceptibility in Plasmodium falciparum clinical isolates from Colombia. Am J Trop Med Hyg. 2021;104:263–70. · DOI
  69. Sa JM, Twu O. Protecting the malaria drug arsenal: halting the rise and spread of amodiaquine resistance by monitoring the pfcrt SVMNT type. Malar J. 2010;9:374. · doi:10.1186/1475-2875-9-374
  70. Petersen I, Gabryszewski SJ, Johnston GL, Dhingra SK, Ecker A, Lewis RE, et al. Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporter. Mol Microbiol. 2015;97:381–95. · DOI
  71. Asare KK, Boampong JN, Afoakwah R, Ameyaw EO, Sehgal R, Quashie NB. Use of proscribed chloroquine is associated with an increased risk of pfcrt T76 mutation in some parts of Ghana. Malar J. 2014;13:246. · doi:10.1186/1475-2875-13-246
  72. Yobi DM, Kayiba NK, Mvumbi DM, Boreux R, Kabututu PZ, Situakibanza HNT, et al. Molecular surveillance of anti-malarial drug resistance in Democratic Republic of Congo: high variability of chloroquinoresistance and lack of amodiaquinoresistance. Malar J. 2020;19:121. · doi:10.1186/s12936-020-03192-x
  73. Chen N, Gao Q, Wang S, Wang G, Gatton M, Cheng Q. No genetic bottleneck in Plasmodium falciparum wild-type pfcrt alleles reemerging in Hainan Island, China, following high-level chloroquine resistance. Antimicrob Agents Chemother. 2008;52:345–7. · doi:10.1128/aac.00711-07
  74. Danquah I, Coulibaly B, Meissner P, Petruschke I, Müller O, Mockenhaupt FP. Selection of pfmdr1 and pfcrt alleles in amodiaquine treatment failure in north-western Burkina Faso. Acta Trop. 2010;114:63–6. · doi:10.1016/j.actatropica.2009.12.008
  75. Mwai L, Kiara SM, Abdirahman A, Pole L, Rippert A, Diriye A, et al. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother. 2009;53:5069–73. · DOI · Paper page
  76. Maiga H, Grivoyannis A, Sagara I, Traore K, Traore OB, Tolo Y, et al. Selection of pfcrt K76 and pfmdr1 N86 Coding Alleles after uncomplicated malaria treatment by artemether-lumefantrine in Mali. Int J Mol Sci. 2021;22:6057. · doi:10.3390/ijms22116057
  77. Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jovel I, Hjalmarsson A, et al. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania. Malar J. 2013;12:103. · DOI
  78. Sisowath C, Petersen I, Veiga MI, Mårtensson A, Premji Z, Björkman A, et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis. 2009;199:750–7. · DOI · Paper page
  79. Bai Y, Zhang J, Geng J, Xu S, Deng S, Zeng W, et al. Longitudinal surveillance of drug resistance in Plasmodium falciparum isolates from the China–Myanmar border reveals persistent circulation of multidrug resistant parasites. Int J Parasitol Drugs Drug Resist. 2018;8:320–8. · DOI
  80. Pelleau S, Moss EL, Dhingra SK, Volney B, Casteras J, Gabryszewski SJ, et al. Adaptive evolution of malaria parasites in French Guiana: reversal of chloroquine resistance by acquisition of a mutation in pfcrt. Proc Natl Acad Sci USA. 2015;112:11672–7. · DOI
  81. Andriantsoanirina V, Ratsimbasoa A, Bouchier C, Tichit M, Jahevitra M, Rabearimanana S, et al. Chloroquine clinical failures in P. falciparum malaria are associated with mutant pfmdr-1, Not Pfcrt in Madagascar. PLoS ONE. 2010;5:e13281. · DOI
  82. Rosario VE, Walliker D, Hall R, Beale GH. Persistance of drug-resistant malaria parasites. The Lancet. 1978;311:185–7. · doi:10.1016/s0140-6736(78)90616-5
  83. Simwela NV, Hughes KR, Roberts AB, Rennie MT, Barrett MP, Waters AP. Experimentally engineered mutations in a ubiquitin hydrolase, UBP-1, modulate in vivo susceptibility to artemisinin and chloroquine in Plasmodium berghei. Antimicrob Agents Chemother. 2020;64:e02484-e2519. · DOI
  84. Ikeda M, Hirai M, Tachibana SI, Mori T, Mita T. Isolation of mutants with reduced susceptibility to piperaquine from a mutator of the rodent malaria parasite Plasmodium berghei. Front Cell Infect Microbiol. 2021;11: 672691. · DOI
  85. Lewis IA, Wacker M, Olszewski KL, Cobbold SA, Baska KS, Tan A, et al. Metabolic QTL analysis links chloroquine resistance in Plasmodium falciparum to impaired hemoglobin catabolism. PLoS Genet. 2014;10: e1004085. · DOI
  86. Gabryszewski SJ, Modchang C, Musset L, Chookajorn T, Fidock DA. Combinatorial genetic modeling of pfcrt-mediated drug resistance evolution in Plasmodium falciparum. Mol Biol Evol. 2016;33:1554–70. · DOI
  87. Wicht KJ, Small-Saunders JL, Hagenah LM, Mok S, Fidock DA. Mutant pfcrt can mediate piperaquine resistance in African Plasmodium falciparum with reduced fitness and increased susceptibility to other antimalarials. J Infect Dis. 2022;226:2021–9. · doi:10.1093/infdis/jiac365
  88. Hayward R, Saliba KJ, Kirk K. pfmdr1 mutations associated with chloroquine resistance incur a fitness cost in Plasmodium falciparum. Mol Microbiol. 2005;55:1285–95. · doi:10.1111/j.1365-2958.2004.04470.x
  89. Amambua-Ngwa A, Button-Simons KA, Li X, Kumar S, Brenneman KV, Ferrari M, et al. Chloroquine resistance evolution in Plasmodium falciparum is mediated by the putative amino acid transporter AAT1. Nat Microbiol. 2023;8:1213–26. · DOI
  90. Reilly HB, Wang H, Steuter JA, Marx AM, Ferdig MT. Quantitative dissection of clone-specific growth rates in cultured malaria parasites. Int J Parasitol. 2007;37:1599. · DOI
  91. Wacker MA, Turnbull LB, Walker LA, Mount MC, Ferdig MT. Quantification of multiple infections of Plasmodium falciparum in vitro. Malar J. 2012;11:180. · DOI
  92. Rønn AM, Msangeni HA, Mhina J, Wernsdorfer WH, Bygbjerg IC. High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. Trans R Soc Trop Med Hyg. 1996;90:179–81. · DOI
  93. Deloron P, Mayombo J, Le Cardinal A, Mezui-Me-Ndong J, Bruzi-Baert C, Lekoulou F, et al. Sulfadoxine-pyrimethamine for the treatment of Plasmodium falciparum malaria in Gabonese children. Trans R Soc Trop Med Hyg. 2000;94:188–90. · DOI
  94. Lege-Oguntoye L, Adagu SI, Werblinska B, Ogala WN, Slotboom AB. Resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine combination in semi-immune children in Zaria, northern Nigeria. Trans R Soc Trop Med Hyg. 1990;84:505–6. · DOI
  95. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis. 2002;2:209–18. · DOI · Paper page
  96. Espinal TCA, Cortes CGT, Guerra P, Arias AE. Sensitivity of Plasmodium falciparum to antimalarial drugs in Colombia. Am J Trop Med Hyg. 1985;34:675–80. · doi:10.4269/ajtmh.1985.34.675
  97. Cortese JF, Caraballo A, Contreras CE, Plowe CV. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis. 2002;186:999–1006. · DOI · Paper page
  98. Juma DW, Omondi AA, Ingasia L, Opot B, Cheruiyot A, Yeda R, et al. Trends in drug resistance codons in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Kenyan parasites from 2008 to 2012. Malar J. 2014;13:250. · DOI
  99. Spalding MD, Eyase FL, Akala HM, Bedno SA, Prigge ST, Coldren RL, et al. Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya. Malar J. 2010;9:338. · DOI
  100. Abdul-Ghani R, Farag HF, Allam AF. Sulfadoxine-pyrimethamine resistance in Plasmodium falciparum: a zoomed image at the molecular level within a geographic context. Acta Trop. 2013;125:163–90. · DOI
  101. Basuki S, Fitriah, Risamasu PM, Kasmijati, Ariami P, Riyanto S, et al. Origins and spread of novel genetic variants of sulfadoxine–pyrimethamine resistance in Plasmodium falciparum isolates in Indonesia. Malar J. 2018;17:475. · DOI
  102. Severini C, Menegon M. Resistance to antimalarial drugs: an endless world war against Plasmodium that we risk losing. J Glob Antimicrob Resist. 2015;3:58–63. · DOI
  103. Yamauchi M, Hirai M, Tachibana SI, Mori T, Mita T. Fitness of sulfadoxine-resistant Plasmodium berghei harboring a single mutation in dihydropteroate synthase (DHPS). Acta Trop. 2021;222: 106049. · DOI
  104. Osoti V, Akinyi M, Wamae K, Kimenyi KM, de Laurent Z, Ndwiga L, et al. Targeted amplicon deep sequencing for monitoring antimalarial resistance markers in western Kenya. Antimicrob Agents Chemother. 2022;66: e0194521. · DOI
  105. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185:380–8. · DOI · Paper page
  106. Kateera F, Nsobya SL, Tukwasibwe S, Hakizimana E, Mutesa L, Mens PF, et al. Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. Acta Trop. 2016;164:329–36. · DOI
  107. Mbogo GW, Nankoberanyi S, Tukwasibwe S, Baliraine FN, Nsobya SL, Conrad MD, et al. Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda. Am J Trop Med Hyg. 2014;91:54–61. · DOI
  108. Khim N, Bouchier C, Ekala MT, Incardona S, Lim P, Legrand E, et al. Countrywide survey shows very high prevalence of Plasmodium falciparum multilocus resistance genotypes in Cambodia. Antimicrob Agents Chemother. 2005;49:3147–52. · DOI
  109. Lin LY, Li J, Huang HY, Liang XY, Jiang TT, Chen JT, et al. Trends in molecular markers associated with resistance to sulfadoxine-pyrimethamine (SP) among Plasmodium falciparum isolates on Bioko Island, Equatorial Guinea: 2011–2017. Infect Drug Resist. 2020;13:1203–12. · DOI
  110. Voumbo-Matoumona DF, Kouna LC, Madamet M, Maghendji-Nzondo S, Pradines B, Lekana-Douki JB. Prevalence of Plasmodium falciparum antimalarial drug resistance genes in southeastern Gabon from 2011 to 2014. Infect Drug Resist. 2018;11:1329–38. · DOI
  111. McCollum AM, Mueller K, Villegas L, Udhayakumar V, Escalante AA. Common origin and fixation of Plasmodium falciparum dhfr and dhps mutations associated with sulfadoxine-pyrimethamine resistance in a low-transmission area in South America. Antimicrob Agents Chemother. 2007;51:2085–91. · DOI
  112. Kuesap J, Suphakhonchuwong N, Kalawong L, Khumchum N. Molecular markers for sulfadoxine/pyrimethamine and chloroquine resistance in Plasmodium falciparum in Thailand. Korean J Parasitol. 2022;60:109–16. · doi:10.3347/kjp.2022.60.2.109
  113. Sugaram R, Suwannasin K, Kunasol C, Mathema VB, Day NPJ, Sudathip P, et al. Molecular characterization of Plasmodium falciparum antifolate resistance markers in Thailand between 2008 and 2016. Malar J. 2020;19:107. · doi:10.1186/s12936-020-03176-x
  114. Artimovich E, Schneider K, Taylor TE, Kublin JG, Dzinjalamala FK, Escalante AA, et al. Persistence of sulfadoxine-pyrimethamine resistance despite reduction of drug pressure in Malawi. J Infect Dis. 2015;212:694–701. · DOI
  115. Pacheco MA, Schneider KA, Cheng Q, Munde EO, Ndege C, Onyango C, et al. Changes in the frequencies of Plasmodium falciparum dhps and dhfr drug-resistant mutations in children from Western Kenya from 2005 to 2018: the rise of Pfdhps S436H. Malar J. 2020;19:378. · DOI
  116. Iriemenam NC, Shah M, Gatei W, van Eijk AM, Ayisi J, Kariuki S, et al. Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya. Malar J. 2012;11:134. · DOI · Paper page
  117. Tessema SK, Kassa M, Kebede A, Mohammed H, Leta GT, Woyessa A, et al. Declining trend of Plasmodium falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant alleles after the withdrawal of sulfadoxine-pyrimethamine in North Western Ethiopia. PLoS ONE. 2015;10: e0126943. · DOI
  118. Raman J, Sharp B, Kleinschmidt I, Roper C, Streat E, Kelly V, et al. Differential effect of regional drug pressure on dihydrofolate reductase and dihydropteroate synthetase mutations in southern Mozambique. Am J Trop Med Hyg. 2008;78:256–61. · DOI
  119. Zhou Z, Griffing SM, de Oliveira AM, McCollum AM, Quezada WM, Arrospide N, et al. Decline in sulfadoxine-pyrimethamine-resistant alleles after change in drug policy in the Amazon region of Peru. Antimicrob Agents Chemother. 2008;52:739–41. · DOI
  120. Hopp CS, Sinnis P. The innate and adaptive response to mosquito saliva and Plasmodium sporozoites in the skin. Ann N Y Acad Sci. 2015;1342:37–43. · DOI
  121. Jelinek T, Kilian AH, Curtis J, Duraisingh MT, Kabagambe G, von Sonnenburg F, et al. Plasmodium falciparum: selection of serine 108 of dihydrofolate reductase during treatment of uncomplicated malaria with co-trimoxazole in Ugandan children. Am J Trop Med Hyg. 1999;61:125–30. · DOI
  122. Suthar AB, Vitoria MA, Nagata JM, Anglaret X, Mbori-Ngacha D, Sued O, et al. Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis. Lancet HIV. 2015;2:e137–50. · DOI
  123. Huijben S, Macete E, Mombo-Ngoma G, Ramharter M, Kariuki S, Desai M, et al. Counter-selection of antimalarial resistance polymorphisms by intermittent preventive treatment in pregnancy. J Infect Dis. 2020;221:293–303.
  124. Hamel MJ, Greene C, Chiller T, Ouma P, Polyak C, Otieno K, et al. Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults? Am J Trop Med Hyg. 2008;79:320–30. · DOI
  125. Thera MA, Sehdev PS, Coulibaly D, Traore K, Garba MN, Cissoko Y, et al. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis. 2005;192:1823–9. · DOI · Paper page
  126. Abdel-Muhsin AA, Mackinnon MJ, Awadalla P, Ali E, Suleiman S, Ahmed S, et al. Local differentiation in Plasmodium falciparum drug resistance genes in Sudan. Parasitology. 2003;126:391–400. · doi:10.1017/s0031182003003020
  127. Contreras C, Cortese J, Caraballo A, Plowe C. Genetics of drug-resistant Plasmodium falciparum malaria in the Venezuelan state of Bolivar. Am J Trop Med Hyg. 2002;67:400–5. · DOI
  128. Gutman J, Kachur SP, Slutsker L, Nzila A, Mutabingwa T. Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy. Malar J. 2012;11:39. · DOI
  129. Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011;10:263. · DOI · Paper page
  130. Nayebare P, Asua V, Conrad MD, Kajubi R, Kakuru A, Nankabirwa JI, et al. Associations between malaria-preventive regimens and Plasmodium falciparum drug resistance-mediating polymorphisms in Ugandan pregnant women. Antimicrob Agents Chemother. 2020;64:e01047-e1120. · DOI
  131. Barnes KI, White NJ. Population biology and antimalarial resistance: the transmission of antimalarial drug resistance in Plasmodium falciparum. Acta Trop. 2005;94:230–40. · DOI
  132. Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg. 1993;87:75–8. · DOI · Paper page
  133. Shinondo CJ, Lanners HN, Lowrie RC, Wiser MF. Effect of pyrimethamine resistance on sporogony in a Plasmodium berghei/Anopheles stephensi model. Exp Parasitol. 1994;78:194–202. · doi:10.1006/expr.1994.1019
  134. Chen K, Sun L, Lin Y, Fan Q, Zhao Z, Hao M, et al. Competition between Plasmodium falciparum strains in clinical infections during in vitro culture adaptation. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2014;24:105–10.
  135. Nsobya SL, Kiggundu M, Joloba M, Dorsey G, Rosenthal PJ. Complexity of Plasmodium falciparum clinical samples from Uganda during short-term culture. J Infect Dis. 2008;198:1554–7. · doi:10.1086/592506
  136. Sandefur CI, Wooden JM, Quaye IK, Sirawaraporn W, Sibley CH. Pyrimethamine-resistant dihydrofolate reductase enzymes of Plasmodium falciparum are not enzymatically compromised in vitro. Mol Biochem Parasitol. 2007;154:1–5. · doi:10.1016/j.molbiopara.2007.03.009
  137. Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci USA. 1997;94:1124–9. · DOI · Paper page
  138. Brown KM, Costanzo MS, Xu W, Roy S, Lozovsky ER, Hartl DL. Compensatory mutations restore fitness during the evolution of dihydrofolate reductase. Mol Biol Evol. 2010;27:2682–90. · DOI
  139. Costanzo MS, Hartl DL. The evolutionary landscape of antifolate resistance in Plasmodium falciparum. J Genet. 2011;90:187–90. · doi:10.1007/s12041-011-0072-z
  140. Kümpornsin K, Modchang C, Heinberg A, Ekland EH, Jirawatcharadech P, Chobson P, et al. Origin of robustness in generating drug-resistant malaria parasites. Mol Biol Evol. 2014;31:1649–60. · DOI
  141. Lozovsky ER, Chookajorn T, Brown KM, Imwong M, Shaw PJ, Kamchonwongpaisan S, et al. Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc Natl Acad Sci USA. 2009;106:12025–30. · DOI · Paper page
  142. Ogbunugafor CB, Hartl D. A pivot mutation impedes reverse evolution across an adaptive landscape for drug resistance in Plasmodium vivax. Malar J. 2016;15:40. · DOI
  143. Fohl LM, Roos DS. Fitness effects of DHFR-TS mutations associated with pyrimethamine resistance in apicomplexan parasites. Mol Microbiol. 2003;50:1319–27. · DOI
  144. Bridgford JL, Xie SC, Cobbold SA, Pasaje CFA, Herrmann S, Yang T, et al. Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome. Nat Commun. 2018;9:3801. · DOI · Paper page
  145. Pasupureddy R, Atul, Seshadri S, Pande V, Dixit R, Pandey KC. Current scenario and future strategies to fight artemisinin resistance. Parasitol Res. 2019;118:29–42. · DOI
  146. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67. · DOI · Paper page
  147. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5. · DOI · Paper page
  148. Mbengue A, Bhattacharjee S, Pandharkar T, Liu H, Estiu G, Stahelin RV, et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature. 2015;520:683–7. · DOI · Paper page
  149. Kagoro FM, Barnes KI, Marsh K, Ekapirat N, Mercado CEG, Sinha I, et al. Mapping genetic markers of artemisinin resistance in Plasmodium falciparum malaria in Asia: a systematic review and spatiotemporal analysis. Lancet Microbe. 2022;3:e184–92. · DOI
  150. Chenet SM, Akinyi Okoth S, Huber CS, Chandrabose J, Lucchi NW, Talundzic E, et al. Independent emergence of the Plasmodium falciparum kelch Propeller domain mutant allele C580Y in Guyana. J Infect Dis. 2016;213:1472–5. · DOI
  151. Ndwiga L, Kimenyi KM, Wamae K, Osoti V, Akinyi M, Omedo I, et al. A review of the frequencies of Plasmodium falciparum Kelch 13 artemisinin resistance mutations in Africa. Int J Parasitol Drugs Drug Resist. 2021;16:155–61. · DOI
  152. Stokes BH, Dhingra SK, Rubiano K, Mok S, Straimer J, Gnädig NF, et al. Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. Elife. 2021;10:e66277. · DOI · Paper page
  153. Dieng CC, Morrison V, Donu D, Cui L, Amoah L, Afrane Y, et al. Distribution of Plasmodium falciparum k13 gene polymorphisms across transmission settings in Ghana. BMC Infect Dis. 2023;23:801. · DOI
  154. Lu F, He XL, Richard C, Cao J. A brief history of artemisinin: Modes of action and mechanisms of resistance. Chin J Nat Med. 2019;17:331–6.
  155. Abamecha A, El-Abid H, Yilma D, Addisu W, Ibenthal A, Bayih AG, et al. Genetic diversity and genotype multiplicity of Plasmodium falciparum infection in patients with uncomplicated malaria in Chewaka district, Ethiopia. Malar J. 2020;19:203. · DOI
  156. Juliano JJ, Porter K, Mwapasa V, Sem R, Rogers WO, Ariey F, et al. Exposing malaria in-host diversity and estimating population diversity by capture-recapture using massively parallel pyrosequencing. Proc Natl Acad Sci USA. 2010;107:20138–43. · DOI
  157. Sondo P, Derra K, Lefevre T, Diallo-Nakanabo S, Tarnagda Z, Zampa O, et al. Genetically diverse Plasmodium falciparum infections, within-host competition and symptomatic malaria in humans. Sci Rep. 2019;9:127. · doi:10.1038/s41598-018-36493-y
  158. Phyo AP, Ashley EA, Anderson TJC, Bozdech Z, Carrara VI, Sriprawat K, et al. Declining efficacy of artemisinin combination therapy against P. Falciparum malaria on the Thai-Myanmar border (2003–2013): the role of parasite genetic factors. Clin Infect Dis. 2016;63:784–91. · DOI · Paper page
  159. Zheng S, Liang Y, Wang Z, Liu M, Chen Y, Ai Y, et al. Polymorphisms in the k13-propeller gene in artemisinin-resistant Plasmodium in mice. Infect Drug Resist. 2022;15:6533–44. · DOI
  160. Sá JM, Kaslow SR, Krause MA, Melendez-Muniz VA, Salzman RE, Kite WA, et al. Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model. Proc Natl Acad Sci USA. 2018;115:12513–8. · DOI
  161. Songsungthong W, Kulawonganunchai S, Wilantho A, Tongsima S, Koonyosying P, Uthaipibull C, et al. The Plasmodium berghei RC strain is highly diverged and harbors putatively novel drug resistance variants. PeerJ. 2017;5: e3766. · doi:10.7717/peerj.3766
  162. Peters W, Robinson BL. The chemotherapy of rodent malaria. LVI. Studies on the development of resistance to natural and synthetic endoperoxides. Ann Trop Med Parasitol. 1999;93:325–9. · doi:10.1080/00034983.1999.11813429
  163. Sutherland CJ. Genetic markers of artemisinin resistance in Plasmodium spp. parasites. Emerg Top Life Sci. 2017;1:525–31. · doi:10.1042/etls20170100
  164. Henriques G, Martinelli A, Rodrigues L, Modrzynska K, Fawcett R, Houston DR, et al. Artemisinin resistance in rodent malaria—mutation in the AP2 adaptor μ-chain suggests involvement of endocytosis and membrane protein trafficking. Malar J. 2013;12:118. · DOI
  165. Pollitt LC, Huijben S, Sim DG, Salathé RM, Jones MJ, Read AF. Rapid response to selection, competitive release and increased transmission potential of artesunate-selected Plasmodium chabaudi malaria parasites. PLoS Pathog. 2014;10: e1004019. · DOI
  166. Wang L, Ji H, Ni S, Xu J, Zhang Y, Zhao X, et al. Antimalarial activity and sensitization of chrysosplenetin against artemisinin-resistant genotype Plasmodium berghei k173 potentially via dual-mechanism of maintaining host P-glycoprotein homeostasis mediated by NF-κB p52 or PXR/CAR signaling pathways and regulating heme/haemozoin metabolism. Phytother Res PTR. 2023;37:2939–56. · doi:10.1002/ptr.7789
  167. Straimer J, Gnädig NF, Stokes BH, Ehrenberger M, Crane AA, Fidock DA. Plasmodium falciparum k13 mutations differentially impact ozonide susceptibility and parasite fitness in vitro. MBio. 2017;8:e00172-e217. · DOI
  168. Bunditvorapoom D, Kochakarn T, Kotanan N, Modchang C, Kümpornsin K, Loesbanluechai D, et al. Fitness loss under amino acid starvation in artemisinin-resistant Plasmodium falciparum isolates from Cambodia. Sci Rep. 2018;8:12622. · DOI
  169. Hott A, Tucker MS, Casandra D, Sparks K, Kyle DE. Fitness of artemisinin-resistant Plasmodium falciparum in vitro. J Antimicrob Chemother. 2015;70:2787–96. · DOI
  170. Chotivanich K, Tripura R, Das D, Yi P, Day NPJ, Pukrittayakamee S, et al. Laboratory detection of artemisinin-resistant Plasmodium falciparum. Antimicrob Agents Chemother. 2014;58:3157–61. · DOI
  171. Hunt P, Afonso A, Creasey A, Culleton R, Sidhu ABS, Logan J, et al. Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. Mol Microbiol. 2007;65:27–40. · DOI · Paper page
  172. Peters JM, Chen N, Gatton M, Korsinczky M, Fowler EV, Manzetti S, et al. Mutations in cytochrome b resulting in atovaquone resistance are associated with loss of fitness in Plasmodium falciparum. Antimicrob Agents Chemother. 2002;46:2435–41. · DOI
  173. Preechapornkul P, Imwong M, Chotivanich K, Pongtavornpinyo W, Dondorp AM, Day NPJ, et al. Plasmodium falciparum pfmdr1 amplification, mefloquine resistance, and parasite fitness. Antimicrob Agents Chemother. 2009;53:1509–15. · DOI
  174. Gimode WR, Kiboi DM, Kimani FT, Wamakima HN, Burugu MW, Muregi FW. Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model. Malar J. 2015;14:38. · DOI
  175. Villa M, Berthomieu A, Rivero A. Fitness costs and benefits in response to artificial artesunate selection in Plasmodium. Peer Comm J. 2022;2: e74. · doi:10.24072/pcjournal.200
  176. Beier JC. Malaria parasite development in mosquitoes. Annu Rev Entomol. 1998;43:519–43. · DOI · Paper page
  177. Bennink S, Kiesow MJ, Pradel G. The development of malaria parasites in the mosquito midgut. Cell Microbiol. 2016;18:905–18. · DOI
  178. Smith RC, Vega-Rodríguez J, Jacobs-Lorena M. The Plasmodium bottleneck: malaria parasite losses in the mosquito vector. Mem Inst Oswaldo Cruz. 2014;109:644–61. · DOI · Paper page
  179. Read AF, Huijben S. Perspective: Evolutionary biology and the avoidance of antimicrobial resistance. Evol Appl. 2009;2:40–51. · DOI
  180. Berry A, Menard S, Nsango SE, Abate L, Concordet D, Tchioffo Tsapi M, et al. The rare, the best: spread of antimalarial-resistant Plasmodium falciparum parasites by Anopheles mosquito vectors. Microbiol Spectr. 2021;9: e0085221. · doi:10.1128/spectrum.00852-21
  181. Lapp Z, Obala AA, Abel L, Rasmussen DA, Sumner KM, Freedman E, et al. Plasmodium falciparum genetic diversity in coincident human and mosquito hosts. MBio. 2022;13: e0227722. · doi:10.1128/mbio.02277-22
  182. Mendes C, Salgueiro P, Gonzalez V, Berzosa P, Benito A, do Rosário VE, et al. Genetic diversity and signatures of selection of drug resistance in Plasmodium populations from both human and mosquito hosts in continental Equatorial Guinea. Malar J. 2013;12:114. · DOI
  183. Goodman CD, Siregar JE, Mollard V, Vega-Rodríguez J, Syafruddin D, Matsuoka H, et al. Parasites resistant to the antimalarial atovaquone fail to transmit by mosquitoes. Science. 2016;352:349–53. · DOI
  184. Mharakurwa S, Matsena-Zingoni Z, Mudare N, Matimba C, Gara TX, Makuwaza A, et al. Steep rebound of chloroquine-sensitive Plasmodium falciparum in Zimbabwe. J Infect Dis. 2021;223:306–9. · doi:10.1093/infdis/jiaa368
  185. Mharakurwa S, Kumwenda T, Mkulama MAP, Musapa M, Chishimba S, Shiff CJ, et al. Malaria antifolate resistance with contrasting Plasmodium falciparum dihydrofolate reductase (dhfr) polymorphisms in humans and Anopheles mosquitoes. Proc Natl Acad Sci USA. 2011;108:18796–801. · DOI
  186. Conrad MD, Mota D, Musiime A, Kilama M, Rek J, Kamya M, et al. Comparative Prevalence of Plasmodium falciparum resistance-associated genetic polymorphisms in parasites infecting humans and mosquitoes in Uganda. Am J Trop Med Hyg. 2017;97:1576–80. · doi:10.4269/ajtmh.17-0351
  187. Zhou Z, Gimnig JE, Sergent SB, Liu Y, Abong’o B, Otieno K, et al. Temporal trends in molecular markers of drug resistance in Plasmodium falciparum in human blood and profiles of corresponding resistant markers in mosquito oocysts in Asembo, western Kenya. Malar J. 2022;21:265. · DOI
  188. Davis BH, Poon AFY, Whitlock MC. Compensatory mutations are repeatable and clustered within proteins. Proc R Soc B Biol Sci. 2009;276:1823–7. · DOI
  189. Andersson DI. Persistence of antibiotic resistant bacteria. Curr Opin Microbiol. 2003;6:452–6. · DOI · Paper page
  190. Durão P, Balbontín R, Gordo I. Evolutionary mechanisms shaping the maintenance of antibiotic resistance. Trends Microbiol. 2018;26:677–91. · DOI · Paper page
  191. Levin BR, Perrot V, Walker N. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics. 2000;154:985–97. · DOI · Paper page
  192. Ffrench-Constant RH, Bass C. Does resistance really carry a fitness cost? Curr Opin Insect Sci. 2017;21:39–46. · doi:10.1016/j.cois.2017.04.011
  193. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol. 1996;70:3763–9. · DOI · Paper page
  194. González-Ortega E, Ballana E, Badia R, Clotet B, Esté JA. Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1. Antiviral Res. 2011;92:479–83. · doi:10.1016/j.antiviral.2011.10.010
  195. Martinez-Picado J, Martínez MA. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res. 2008;134:104–23. · DOI
  196. Heinberg A, Siu E, Stern C, Lawrence EA, Ferdig MT, Deitsch KW, et al. Direct evidence for the adaptive role of copy number variation on antifolate susceptibility in Plasmodium falciparum. Mol Microbiol. 2013;88:702–12. · doi:10.1111/mmi.12162
  197. Summers RL, Dave A, Dolstra TJ, Bellanca S, Marchetti RV, Nash MN, et al. Diverse mutational pathways converge on saturable chloroquine transport via the malaria parasite’s chloroquine resistance transporter. Proc Natl Acad Sci USA. 2014;111:e1759–67. · DOI
  198. Jiang H, Patel JJ, Yi M, Mu J, Ding J, Stephens R, et al. Genome-wide compensatory changes accompany drug-selected mutations in the Plasmodium falciparum crt gene. PLoS ONE. 2008;3: e2484. · DOI
  199. Mesén-Ramírez P, Bergmann B, Elhabiri M, Zhu L, von Thien H, Castro-Peña C, et al. The parasitophorous vacuole nutrient channel is critical for drug access in malaria parasites and modulates the artemisinin resistance fitness cost. Cell Host Microbe. 2021;29:1774-1787.e9. · DOI
  200. Putaporntip C, Kuamsab N, Kosuwin R, Tantiwattanasub W, Vejakama P, Sueblinvong T, et al. Natural selection of K13 mutants of Plasmodium falciparum in response to artemisinin combination therapies in Thailand. Clin Microbiol Infect. 2016;22(285):e1-8.

200 of 212 shown

Cited by

See all 12

Metadata

Authors
Segovia, X., Srivastava, B., Serrato-Arroyo, S., Guerrero, A., & Huijben, S.
Venue
Malaria Journal
Published
2025-03-01
Volume
24
Issue
1
ISSN
1475-2875
Cited by
12
References
5
Language
en
Licence
Funders
NSF (2047572 and 2052363)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessing fitness costs in malaria parasites: a comprehensive review and implications for drug resistance management. https://app.cochat.ai/papers/10.1186/s12936-025-05286-w
The paper
Segovia, X., Srivastava, B., Serrato-Arroyo, S., Guerrero, A., & Huijben, S. (2025). Assessing fitness costs in malaria parasites: a comprehensive review and implications for drug resistance management. Malaria Journal. https://doi.org/10.1186/s12936-025-05286-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.